Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older DOI Creative Commons
Yingping Chen,

Xinpei Zhang,

Lihui Gong

и другие.

Expert Review of Vaccines, Год журнала: 2023, Номер 22(1), С. 1079 - 1090

Опубликована: Окт. 25, 2023

Because SARS-CoV-2 mutations and immunity wane over time, a third dose of heterologous COVID-19 vaccine is proposed for individuals primed with inactivated vaccine.We conducted single-center, open-label trial to assess the safety, immunogenicity, immune-persistence BBIBP-CorV/ZF2001 prime-boost vaccination in Chinese adults. 480 participants who had been two doses BBIBP-CorV, received ZF2001 after an interval 3-4, 5-6, or 7-9 months.The overall incidence adverse reactions within 30 days was 5.83%. No serious were reported. The respective geometric mean titers (GMTs) neutralizing antibodies months groups at baseline 2.06, 2.02, 2.10; which increased 55.42, 63.45, 62.06 on day 14; then decreased 17.53, 23.79, 26.73 30; before finally waning 8.29, 9.24, 9.51 180. After booster, three showed no significant differences GMTs. GMTs lower older than younger participants.A safe immunogenic. Prime-boost intervals did not affect immune response. response weaker adults adults.NCT05205083.

Язык: Английский

Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey DOI Creative Commons

Shijie Qin,

Yanhua Li, Likui Wang

и другие.

Emerging Microbes & Infections, Год журнала: 2023, Номер 12(2)

Опубликована: Сен. 11, 2023

Coronavirus disease 2019 (COVID-19) cases in China has grown rapidly after adjustment of the dynamic zero-COVID-19 strategy. However, how different vaccination states affect symptoms, severity and post COVID conditions was unclear. Here, we used an online questionnaire to investigate infection status severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among 11,897 participants, with 55.55% positive 28.42% negative. The common COVID-19 symptoms were fatigue (73.31%), cough (70.02%), fever (65.25%) overall soreness (58.64%); self-reported asymptomatic accounted for 0.7% participants. persistent at 1 month included (48.7%), drowsiness (34.3%), (30.1%), decreased exercise ability (23.1%) pharyngeal discomfort (19.4%), which reduced by more than 200% months. Participants complications such as chronic obstructive pulmonary disease, diseases, diabetes, hypertension, etc. have a higher proportion hospitalization longer recovery time (

Язык: Английский

Процитировано

19

The impact of risk perception and institutional trust on COVID-19 vaccine hesitancy in China DOI Creative Commons
Guiwu Chen, Yiyun Yao, Yaowen Zhang

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)

Опубликована: Янв. 28, 2024

Vaccination has become the primary means for citizens to prevent severe morbidity and mortality during pandemic. However, vaccine hesitancy poses a major threat global public health security. Based on data from Chinese General Social Survey in 2021, this study aims explore socio-political aspects of COVID-19 hesitancy, focusing relationship between risk perceptions, institutional trust hesitancy. Among samples, 39.8% respondents exhibited 48.9% had high awareness COVID-19, 74.6% presented level institutions. The results showed that higher perception are negatively correlated with (p < .001). Institutional no statistically significant moderating effect association but role influencing is more at lower perceptions risk. Furthermore, regional variations factors contributing were demonstrated China. These findings have important implications developing strategies address

Язык: Английский

Процитировано

5

Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience DOI Creative Commons
Wu Liu,

Zhong‐Han He,

Ling Huang

и другие.

Advanced Science, Год журнала: 2024, Номер 11(23)

Опубликована: Март 27, 2024

Abstract COVID‐19 can lead to adverse outcomes in patients with pre‐existing diseases. Azvudine has been approved for treating China, but the real‐world data is limited. It aimed investigate efficacy of and cardiovascular Patients confirmed diseases are retrospectively enrolled. The primary outcome all‐cause death during hospitalization. Overall, 351 included, a median age 74 years, 44% female. 212 (60.6%) severe cases. used 106 (30.2%) not 245 (69.8%). 72 died After multivariate adjustment, who received lower risk (hazard ratio: 0.431; 95% confidence interval: 0.252–0.738; p = 0.002) than controls. therapy also associated risks shock acute kidney injury. For sensitivity analysis propensity score‐matched cohort ( n 90 each group), there significant difference between two groups 0.189; 0.071–0.498; < 0.001). This study indicated that better

Язык: Английский

Процитировано

4

Lactating nurses' experiences of return to work after lifting COVID-19 lockdown: A qualitative study DOI Creative Commons
Suya Li, W Zhang, Yu Liu

и другие.

Heliyon, Год журнала: 2023, Номер 10(1), С. e23761 - e23761

Опубликована: Дек. 24, 2023

AimTo explore the lactating nurses' experiences of return to work after lifting COVID-19 lockdown.BackgroundReturn is a key reason for low rates breastfeeding. Especially lockdown, case counts reached recorded highs. So nurses face more challenges when they work.MethodThe empirical phenomenology method was used conduct qualitative study. Lactating were recruited in tertiary hospital through purposive and snowball sampling, participated semi-structured video interviews. Colaizzi's analyze data.ResultsThree themes 10 sub-themes emerged from interview data 15 participants. The first theme "preparation work", which helped adapt quickly. second "experiences work". inconvenience pumping mentioned repeatedly. In addition, flexible schedule highlighted. third infection". attitudes toward breastfeeding differed due different perceptions COVID-19.ConclusionsLactation easily interrupted or stopped returned lockdown. Recommendations include further provision longer periods leave, working arrangements, separate facilities breast pumping, strategies epidemics.

Язык: Английский

Процитировано

6

Investigating the association between perceived risk levels and commuting mode shifts after the lifting of the COVID-19 pandemic prevention and control policies DOI Creative Commons

Jiankun Yang,

Yuhang Zhang,

Qiuyan Zhao

и другие.

Transportation Research Interdisciplinary Perspectives, Год журнала: 2024, Номер 25, С. 101085 - 101085

Опубликована: Май 1, 2024

There is a research gap in understanding people's perceived risks and their commute mode shifts after the major shift anti-pandemic policies. Our study aims to reveal relationship between commuters' commuting transfers specific context of canceling We conducted an online sample survey residents 6 neighborhoods one month lifting policies Kunming, China. Measured risk data suggested that score 23 ∼ 30 accounted for 62 % respondents, who were defined as high-perceived group; while 14 22 36 middle-perceived only 2 respondents with 14. Commuting transfer statistics showed 22.2 switched from other modes private cars, which 56.1 came public transportation. Conversely, out 81 car commuters, 3 moved modes. used nonparametric tests find there group differences shifts. Specifically, proportion commuters levels shifted travel cars was 11% larger than levels. Public more likely switch active commuters. The test results also single variables such ownership, distance, age, marital status significantly correlated distribution shifting mode. Furthermore, we employed binary logistic regression model higher levels, longer distances, or ownership conclusion this COVID-19 pandemic prevention control increases level pushes them commuting. It necessary pre-estimating level, pre-judging changes daily behaviors before deciding cancel

Язык: Английский

Процитировано

0

Clinical Characteristics of Diabetic Patients with COVID-19 During the Full Liberalization of the Pandemic DOI Creative Commons

Zejian Zhuang,

Jingyuan Li,

Lingfeng Sun

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Май 24, 2024

Abstract Diabetes is an important comorbidity of COVID-19. This study aimed to compare the clinical course and outcomes COVID-19 patients with without diabetes. We enrolled 321 hospitalized from Third Xiangya Hospital (Hunan, China) between December 20, 2021, March 1, including 158 diabetes 163 Data medical records, characteristics, coexisting conditions, complications, laboratory tests, radiographic studies, treatments outcomes, were extracted analyzed. Among type 2 diabetes, several biochemical parameters, such as systolic blood pressure [137.00 (IQR: 122.00-148.50) vs. 126.00 116.00-137.00), P<0.001], CRP [64.25 28.16-129.83) 44.13 17.56-87.26), P = 0.005], PCT [0.11 0.06-0.44) 0.08 (IQR : 0.05-0.14), 0.002], urea nitrogen [15.40 10.62-24.44) 10.34 (IQR:7.56-15.14), < 0.001), In terms symptoms, had pleural effusion [17.3% 7.5%, P=0.010], fever [39.0% 60.7%, nausea vomiting [10.4% 1.2%, fatigue symptoms [22.7% vs 12.9%, P=0.022]. There significant differences in comorbidities, hypertension (71.2% 37.0%, P<0.001) chronic kidney disease (6.4% 18.5%, P=0.001). The statistically difference treatment those was mainly reflected use azvudine (15.9% 40.7%, P<0.001). Regression analysis revealed that lymphocyte ratio (0R=0.925, 95% CI 0.885-0.966, age (0R=1.025, 1.003-1.048, P=0.027) a effect on severity respiratory failure. Some medication effects survival time, calcification (HR=0.410, 0.193-0.872, P=0.021), (HR=1.935, 1.259-2.975, P=0.003), (HR=1.416, 1.042-1.926, P=0.026), (HR=1.557, 1.032-2.349, P=0.035), antibiotics (HR=1.623, 1.139-2.315, P=0.007) glucocorticoids P=0.005), mechanical ventilation (HR=4.201, 1.883-9.377, Our suggested tend have more severe poorer this relationship requires further exploration.Retrospectively registered.

Язык: Английский

Процитировано

0

WITHDRAWN: Clinical Characteristics of Diabetic Patients with COVID-19 During the Full Liberalization of the Pandemic DOI

Zejian Zhuang,

Jingyuan Li,

Lingfeng Sun

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Июль 17, 2024

Abstract The full text of this preprint has been withdrawn by the authors in order to comply with an institutional policy on preprints. Therefore, do not wish work be cited as a reference.

Язык: Английский

Процитировано

0

What are the frequent complaints voiced by inpatients and physicians amidst the emerging infectious diseases? — An illustrative instance of the COVID-19 DOI Creative Commons

Xixia Feng,

Peiyi Li,

Xuechao Hao

и другие.

BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)

Опубликована: Авг. 7, 2024

Emerging infectious diseases (EIDs) can disrupt the healthcare system, causing regulatory changes that affect healthcare-seeking process and potentially increase patient-physician dissatisfaction. This study aimed to collect analyze patients' physicians' complaints during an EID outbreak inform potential clues regarding medical quality patient safety enhancement in future dealing with EIDs, employing text mining methodologies.

Язык: Английский

Процитировано

0

Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older DOI Creative Commons
Yingping Chen,

Xinpei Zhang,

Lihui Gong

и другие.

Expert Review of Vaccines, Год журнала: 2023, Номер 22(1), С. 1079 - 1090

Опубликована: Окт. 25, 2023

Because SARS-CoV-2 mutations and immunity wane over time, a third dose of heterologous COVID-19 vaccine is proposed for individuals primed with inactivated vaccine.We conducted single-center, open-label trial to assess the safety, immunogenicity, immune-persistence BBIBP-CorV/ZF2001 prime-boost vaccination in Chinese adults. 480 participants who had been two doses BBIBP-CorV, received ZF2001 after an interval 3-4, 5-6, or 7-9 months.The overall incidence adverse reactions within 30 days was 5.83%. No serious were reported. The respective geometric mean titers (GMTs) neutralizing antibodies months groups at baseline 2.06, 2.02, 2.10; which increased 55.42, 63.45, 62.06 on day 14; then decreased 17.53, 23.79, 26.73 30; before finally waning 8.29, 9.24, 9.51 180. After booster, three showed no significant differences GMTs. GMTs lower older than younger participants.A safe immunogenic. Prime-boost intervals did not affect immune response. response weaker adults adults.NCT05205083.

Язык: Английский

Процитировано

0